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Abstract
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis which affects humans and a wide
range of domestic and wild ruminants. The large spread of RVF in Africa and its potential to
emerge beyond its geographic range requires the development of surveillance strategies to
promptly detect the disease outbreaks in order to implement efficient control measures,
which could prevent the widespread of the virus to humans. The Animal Health Mediterra-
nean Network (REMESA) linking some Northern African countries as Algeria, Egypt, Libya,
Mauritania, Morocco, Tunisia with Southern European ones as France, Italy, Portugal and
Spain aims at improving the animal health in theWestern Mediterranean Region since 2009.
In this context, a first assessment of the diagnostic capacities of the laboratories involved in
the RVF surveillance was performed. The first proficiency testing (external quality assess-
ment—EQA) for the detection of the viral genome and antibodies of RVF virus (RVFV) was
carried out from October 2013 to February 2014. Ten laboratories participated from 6 differ-
ent countries (4 from North Africa and 2 from Europe). Six laboratories participated in the ring
trial for both viral RNA and antibodies detection methods, while four laboratories participated
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exclusively in the antibodies detection ring trial. For the EQA targeting the viral RNA detec-
tion methods 5 out of 6 laboratories reported 100% of correct results. One laboratory mis-
identified 2 positive samples as negative and 3 positive samples as doubtful indicating a
need for corrective actions. For the EQA targeting IgG and IgM antibodies methods 9 out of
the 10 laboratories reported 100% of correct results, whilst one laboratory reported all correct
results except one false-positive. These two ring trials provide evidence that most of the par-
ticipating laboratories are capable to detect RVF antibodies and viral RNA thus recognizing
RVF infection in affected ruminants with the diagnostic methods currently available.
Introduction
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis which affects humans and a wide
range of vertebrate hosts causing severe economic losses in adult livestock (primarily sheep,
goats and cattle). The Rift Valley fever virus (RVFV) belongs to the Bunyaviridae family and
the Phlebovirus genus. Its genome consists of 3 single stranded RNA segments, the M
(medium) and L (large) segments are of negative orientation whereas the S (small) segment has
an ambisense polarity [1]. The virus is primarily transmitted by mosquitoes to and among ani-
mals. Known competent vectors belong to the genera Aedes, Culex and Anopheles [2]. Direct
transmission through contact with infected tissue may occur and play an important role in
human infection [2].
The virus was first identified in 1930 along the shores of Lake Naivasha in the greater Rift
Valley of Kenya [3,4]. During the last decades RVFV caused large epidemics in many African
countries as well as Madagascar and the Arabian Peninsula, causing severe economic losses in
breeding of ruminants and hundreds of human deaths [5,6]. Over time, the virus shows little
variation, with one known serotype [7].The wide spread of RVF in Africa requires the develop-
ment of surveillance strategies to promptly detect the disease outbreaks in order to implement
efficient control measures, which could prevent the spillover of the virus to humans. Therefore,
accurate detection of RVFV in animals and mosquitoes is essential. According to the World
Organization for Animal Health-OIE [8], diagnostic methods for RVFV include virus isolation,
reverse-transcription polymerase chain reaction (RT-PCR), and serological tests. Isolation pro-
cedures are expensive, time-consuming and require high biocontainment facilities (biosafety
level 3- BSL3). Therefore several molecular diagnostic tests based on RT-PCR targeting the dif-
ferent segments of the virus genome have been recently developed [9–12], allowing the rapid
and sensitive detection of the virus genome. Among the serological tests, ELISA is the most
widely used technique for IgM and IgG type antibodies detection. Different ELISA formats are
commercially available and others are currently under development [13–18].Virus neutraliza-
tion test (VNT) is the prescribed test for international trade enabling RVFV antibodies detec-
tion in the serum of a large range of animal species. However it is time-consuming and
requires skilled personnel working in BSL3 facilities[8].
The performance of the different techniques applied to the RVF diagnosis may vary between
laboratories. An external quality assessment (EQA) allows the laboratories to monitor the qual-
ity of their diagnosis, evaluate their capacities and, eventually, identify the possible weaknesses
in order to put in place corrective actions.
An Animal Health Mediterranean Network (REMESA) linking six Northern African coun-
tries Algeria, Egypt, Libya, Mauritania, Morocco, Tunisia and four Southern European coun-
tries, France, Italy, Portugal and Spain was created in 2009 with the technical support of the
EQA for the Diagnosis of Rift Valley Fever in the Mediterranean Basin
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OIE and the Food and Agriculture Organization of the United Nations (FAO). The main aim
is to improve the animal health with a particular focus on prevention and control of trans-
boundary animal diseases, including zoonoses, through capacity building, coordination and
practices harmonization. Cyprus, Greece and Malta joined the network in 2013, Jordan and
Lebanon in 2014. The Chief Veterinary Officers (CVOs) members of REMESA recognized
RVF as a priority deserving specific attention. As part of the REMESA, a veterinary diagnostic
laboratory based network (RELABSA) was established to strengthen the national laboratories
scientific and technical level diagnostic capacities. Integrated and inter-operative surveillance
efforts in the region would benefit from the harmonization of the diagnostic procedures as well
as setting in quality assurance for member laboratories.
In September–October 2010, an unprecedented outbreak of RVF was reported in the north-
ern Sahelian region of Mauritania after exceptionally heavy rainfall. At the end of December
2010, a total of 63 cases among humans, including 13 deaths, had been officially reported, but
the true number is probably much higher due to the remoteness of the affected area. Positive
test results were observed by real-time reverse transcription PCR and the virus was isolated
from initially positive serological samples [19].
Therefore, the regional OIE/FAO coordination unit of REMESA (OIE Sub-Regional Repre-
sentation for North Africa and FAO Sub-regional office for North Africa, both located in
Tunis, Tunisia) proposed to the CVOs of REMESA the implementation of a dedicated project,
including laboratory, epidemiology and entomology activities. A specific financial support was
provided to FAO by the French authorities to re-inforce the prevention and control of RVF
(GCP/SNE/001/FRA). This allowed the organization of a first EQA dedicated to the RVFV by
virus genome and antibodies detection in order to perform a first assessment of the diagnostic
capacity of the laboratories involved in the RVF surveillance in the REMESA framework. This
study reports the results from the inter-laboratory ring trials and provides details related to the
diagnostic protocols used for RVF genome and antibodies detection.
Materials and Methods
Call for participation
An invitation letter was sent to the CVOs of the REMESA countries (Algeria, Egypt, France,
Italy, Libya, Morocco, Mauritania, Portugal, Spain and Tunisia) in June 2012 by the Istituto
Zooprofilattico Sperimentale dell’Abruzzo e del Molise– IZSAM. The organization of this trial,
particularly with regard to the logistical and technical aspects, was presented and discussed to
REMESA member countries during a preliminary meeting held in Tunis on 6 and 7 May 2013.
A total of 10 laboratories involved in diagnostics of RVF infections from 6 different countries
expressed their willingness to participate (3 from Algeria, 2 from France, 1 from Mauritania, 2
fromMorocco, 1 from Spain and 1 from Tunisia). Six laboratories participated to both the
viral genome detection by RT-PCR and the specific IgG and IgM antibodies detection. Four
laboratories participated exclusively to the antibodies detection trial. The participation of each
laboratory and the import of panels was officially requested by the organizer and authorized by
the Chief Veterinary Officers of the participating countries.
Specimen preparation
The study included preparation of two different test panels: i) sample panel for viral genome
detection by RT-PCR, ii) sample panel for antibodies detection (IgG and IgM detection) by
ELISA.
Samples for viral genome detection. For the molecular diagnosis of RVFV, each partici-
pant received a coded panel of 15 ruminant sera composed of 5 negative and 10 positive samples.
EQA for the Diagnosis of Rift Valley Fever in the Mediterranean Basin
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The RVF field strain Namibia 2010 (N10) [20] was used to spike negative bovine serum to pre-
pare the positive samples. Briefly, the viral strain was propagated on Vero cells (ATCC1Manas-
sas, USA), the supernatant collected and inactivated as follows: Tris–hydroxymethyl-
aminomethane (Tris) 1 M pH 8.0 was added to the virus suspension and stirred for 10 min at
room temperature. Beta-propiolactone diluted in PBS pH 7.4 was subsequently added to the
virus suspension to a final dilution of the inactivation agent equal to 0.2% (v/v) [21]. Three con-
secutive passages on Vero cells, each followed by real-time quantitative RT-PCR (qRT-PCR)
[10] excluded any residual infectivity. Five different dilutions (1:2, 1:10, 1:50, 1:100, 1:200) of the
viral suspension were added to the RVFV seronegative bovine serum. The viral load was evalu-
ated for each viral dilution by qRT-PCR [10]. The copy number of the RVFV genome was deter-
mined in each spiked sample by using serial dilutions of the linearized plasmid pEX-A (Eurofin
Scientific, Luxemburg) containing the PCR target sequence. The viral load was defined as the
mean value calculated from five replicates of each sample (Tables 1 and 2). Spiked samples were
evaluated to assess their homogeneity and stability. Homogeneity was evaluated by testing 5 rep-
licates of each sample. Stability was evaluated by testing three aliquots of each sample kept at
room temperature and tested at different time intervals [t0, t1 (72 hours) t2 (7 days)]. Negative
samples were prepared from a stock of RVFV seronegative serum. Aliquots of 300 μl were stored
at −80°C and kept frozen until the shipment to individual laboratories.
Samples for antibodies detection by ELISA. For the serological diagnosis of RVF, each
participant received a panel of 15 ruminant sera composed of 5 negative and 10 positive sam-
ples. The positive samples consisted of sera from domestic and wild ruminants: five samples
were from RVFV vaccinated sheep (n = 4) and goats (n = 1) seropositive for IgG. Animals were
vaccinated with the formalin inactivated Rift Valley fever virus commercially available from
the Onderstepoort Biological Product (OBP, Onderstepoort, South Africa). Five samples were
from 5 springboks (Antidorcas marsupialis) found RVF seropositive for both IgG and IgM
according with the results of ELISAs ID Screen1 Rift Valley Fever Competition Multi-species
and ID Screen1 Rift Valley Fever IgM Capture (IDvet, Grabels, France) for IgG and IgM detec-
tion respectively. Negative samples were prepared from a single bovine RVF seronegative
serum (Gibco1 Fetal Bovine Serum, Life Technologies, Carlsbad, USA). To exclude the
Table 1. Results of the EQA for RVFV virus genome detection.
RVF strain Namibia 2010
ID Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Dilution 1:2 1:10 1:50 Neg Neg 1:100 1:200 Neg Neg 1:2 1:10 1:50 Neg 1:100 1:200
RVF copies/μl 106,1 105,4 104,8 104,5 104,2 106,1 105,4 104,8 104,5 104,2
Lab n°
#1* + + + FP - + + - - + + + - + +
#1a* + + + - - + + - - + + + - + +
#2 + + + - - Inc + - - + Inc Inc - FN FN
#7 + + + - - + + - - + + + - + +
#8 + + + - - + + - - + + + - + +
#9 + + + - - + + - - + + + - + +
#10 + + + - - + + - - + + + - + +
Neg: RVFV seronegative bovine serum. + / -: samples identiﬁed as positive or negative by the participants. FP: false positive result. FN: false negative
result. Inc: Inconclusive results.
* Laboratory providing multiple datasets
doi:10.1371/journal.pone.0142129.t001
EQA for the Diagnosis of Rift Valley Fever in the Mediterranean Basin
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presence of any infectious viral particle, the samples were tested by RT-PCR [9] and heated at
56°C for three hours. The inactivation process was assessed as described above. Each set of
samples was evaluated for homogeneity by testing 5 replicates with the above ELISAs. Stability
was evaluated with the ELISA tests cited above by using the number of samples and the time
intervals t0, t1 (72 hours) t2 (7 days).
EQA details
The participants of the EQA were asked to analyze the panels by using the diagnostic proce-
dures routinely used in their laboratories. They were also asked to provide details about the
tests, namely the serological assay(s) used, the protocols for RT-PCR procedure, the manufac-
turer of the RT-PCR instrument and the chemicals for the RNA extraction.
Statistical analysis
The results provided by each participant were classified as correct or incorrect on the basis of
the known samples results in the panels. Results were analyzed by a Bayesian approach [22].
The Beta distribution was calculated and used to define the probability of each laboratory to
give a correct result and the uncertainty of this estimate:
Betaða1; a2Þ ¼
xa11ð1 xÞa21
R1
0
ta11ð1 tÞa21dt
where α1 = correct results +1; α 2 = tested samples−correct results + l
Ethics Statement
The serum samples distributed for the EQA were selected from the samples archive of the
IZSAM, they were not collected specifically for this study. The collection of the samples was
performed before the design of this study. The owner of the animals, the Central Veterinary
Laboratory (CVL) of Windhoek (NA), kept them on pasture, free to graze grasses and forage
Table 2. Results of the EQA for RVFV virus genome detection, cycle threshold (Ct) values.
RVF strain Namibia 2010
ID Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Dilution 1:2 1:10 1:50 Neg Neg 1:100 1:200 Neg Neg 1:2 1:10 1:50 Neg 1:100 1:200
RVF copies/μl 106,1 105,4 104,8 104,5 104,2 106,1 105,4 104,8 104,5 104,2
Lab n°
#1* 22,8 22,9 22,7 35,9 No Ct 23,8 24,6 No Ct No Ct 24,5 21,8 24,7 No Ct 25,8 26,3
#1a* 24,5 22 26,9 No Ct No Ct 26,6 27,7 No Ct No Ct 25,1 22,1 24,8 No Ct 26,4 27,3
#2 31 32 34 No Ct No Ct 39 35 No Ct No Ct 31 38 39 No Ct 42 41
#7 21,6 23,9 26,0 No Ct No Ct 27,7 27,7 No Ct No Ct 21,7 22,7 25,3 No Ct 25,6 31,3
#8 26,8 25,7 28,6 40 40 29,6 29,9 40 40 27,9 26,9 29,2 40 29,6 30,4
#9 22.8 21.6 23.8 No Ct No Ct 24.6 25.7 No Ct No Ct 22.1 22.1 23.7 No Ct 24.7 25.7
#10 26,5 27,3 28,9 No Ct No Ct 29,9 29,7 No Ct No Ct 25,5 27,1 28,6 No Ct 27,1 29,4
Neg: RVFV seronegative bovine serum. No Ct: result above the threshold.
* Laboratory providing multiple datasets
doi:10.1371/journal.pone.0142129.t002
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found in the pasture and provided fresh water ad libitum. Following the notification of Rift
Valley Fever (RVF) virus circulation in Namibia in 2010, CVL decided to protect the animals
from the infection by administering an inactivated vaccine against RVF. Animals were bleed
twice a month for approximately 6 months, in order to assess the sero-conversion. The IZSAM
provided diagnostic support, in the frame of the international cooperation between the IZSAM
and the Namibian Directorate of Veterinary Services, enforced by the Memorandum of Under-
standing signed the 16th December 2004 in Windhoek and the 24th January 2005 in Teramo,
Italy. The activity was funded by Italian Ministry of Health (IZSAM01/10 RC) and only the
CVL and IZSAM veterinarians and trained animal care personnel were allowed to manipulate
and bleed the animals.
Serum samples from springbok were collected by jugular venopuncture during a disease
surveillance program in wildlife in the Ethosa National Park (ENP) in Namibia. Animal dart-
ing, bleeding and post-operative care, as well as radiocollaring and tracking were carried out by
ENP staff to minimize unnecessary stress and injury to the animals. Approval for sample col-
lection was obtained by the Namibian Ministry of Environment and Tourism the 25th October
2010, (research/collection permit n° 1543/2010, 15/11/2010). The vaccination protocol as well
as the collection of the springbok sera could not be submitted to an ethical body for approval,
since Namibia did not apply animal testing regulations.
Results
Ten laboratories participated in the EQA from 6 different countries (4 African and 2 Euro-
pean). The participants were (in alphabetical order by countries): i) Institut National de la
Médecine Vétérinaire, Laboratoire Central Vétérinaire d'Alger, Algeria; ii) Institut National de
la Médecine Vétérinaire, Laboratoire Vétérinaire Régional de Laghouat, Algeria; iii) Institut
National de la Médecine Vétérinaire, Laboratoire Vétérinaire Régional de Tlemcen, Algeria; iv)
Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail
(ANSES), Virology Unit, Laboratory of Lyon, France; v) Centre de Coopération Internationale
en Recherche Agronomique pour le Développement (CIRAD), Montpellier, France; vi) Centre
National d'Elevage et de Recherches Vétérinaires, laboratoire de Virologie, Nouakchott, Mauri-
tania; vii) Office National de Sécurité Sanitaire des Produits Alimentaires (ONSSA), Labora-
toire Régional d'Analyses et de Recherches d'Agadir, Morocco; viii) Office National de Sécurité
Sanitaire des Produits Alimentaires (ONSSA), Laboratoire Régional d'Analyses et de
Recherches de Casablanca, Morocco; ix) Centro de Investigación en Sanidad Animal (CISA-I-
NIA), Laboratory of Emerging and Transboundary Diseases, Valdeolmos (Madrid), Spain; x)
Institut de la Recherche Vétérinaire de Tunisie, Tunisia.
The laboratories in France (CIRAD and ANSES) and in Spain (CISA-INIA) performed the
diagnostic test in BSL-3 facilities. The participating laboratories from African countries, lacking
a BSL-3 facility, used biosafety cabinets and appropriate procedures and personal protective
equipment to manipulate the samples.
Virus genome detection
A total of 7 datasets were received from the 6 laboratories which participated to the EQA for
the virus genome detection panel, including 1 double set from laboratory #1, which used two
different methods (#1 and #1a). All labs used real-time RT-PCR assays. The primer sequences
were from 2 different RT-PCR tests: 3 laboratories (#2, #7, #9) used the method developed by
Drosten et al. [11] targeting the RVFV-M segment whereas 2 laboratories (#1, #8) used the
methods published by Bird et al. [10] and LaBeaud et al. [23] (#10) using the same primers tar-
geting the L segment. One laboratory (#1a) used an unpublished method developed by the
EQA for the Diagnosis of Rift Valley Fever in the Mediterranean Basin
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Friedrich-Loeffler-Institut with the oligonucleotides published by Bird et al. [10] (Table 3).
One single-base mismatch with the Namibia 2010 strain target sequence was present within
the reverse primer of the method developed by Drosten et al. [11] and within the probe of the
RT-PCR assay by Bird et al. [10]. RNA extraction techniques varied among participants: 4 car-
ried out manual extraction with the commercial kits: (#1, #1a, #10) NucleoSpin1 RNA Virus
(Macherey-NagelGmbH & Co. KG, Duren, Germany), (#2) PureLink1 Viral RNA/DNAMini
Kit (Life Technologies, Carlsbad, CA, USA), (#9) QIAamp1 Viral RNAMini Kit (Qiagen,
Venlo, Limburgo, Netherlands), while 2 laboratories relied on automated methods: (#7) BioS-
print 15 workstation (Qiagen, Venlo, Limburgo, Netherlands) and (#8) Arrow Viral NA Kit
(AutoGen Nordiag Holliston, MA, USA). Among the participating labs, 5 RT-PCR instru-
ments were used: (#1, #1a) Swift™ Spectrum 48 Real Time Thermal Cycler (Esco Technologies,
Hatboro, PA, USA), (#2) Applied Biosystems1 7500 Real-Time PCR Systems (Life Technolo-
gies, Carlsbad, CA, USA), (#7, #10) Mx3005P qPCR (Agilent Technologies, Santa Clara, CA,
USA), (#8) iQ5 (BioRad, Hercules, CA, USA), (#9) LightCycler1 480 (Roche, Basilea, Switzer-
land). Reagents used for RT-PCR were: (#1, #8, #9) SuperScript1 III Platinum1One-Step
Quantitative RT-PCR System (Life Technologies, Carlsbad, CA, USA), (#1a) OneStep RT-PCR
Kit (Qiagen, Venlo, Limburgo, Netherlands), (#7) AgPath-ID One-step RT-PCR kit (Life Tech-
nologies, Carlsbad, CA, USA), (#10) Sybr Green Brillant II (Agilent Technologies, Santa Clara,
CA, USA) (Table 3).
Five out of 6 laboratories reported 100% of correct results (Table 1) Ct values provided by
the laboratories are detailed in Table 2. The laboratory providing two different RT-PCR data-
sets produced 100% of correct results and one false-positive result respectively (Table 1). Labo-
ratory #2 misidentified 2 positive samples as negative and 3 positive samples as doubtful
(Tables 1 and 2). The laboratory failing one test result (#1) has a probability of giving a correct
test result higher than 73.6% (Fig 1). For laboratories which correctly classified 15 out of 15
tested samples (labs # 1, 7, 8, 9, 10), the probability of giving a correct result was higher than
82.9%, with a confidence level of 95% (Fig 1).
Table 3. EQA for RVFV virus genome detection, RNA extraction and RT PCR instruments andmethods.
RNA RT PCR
Extraction Puriﬁcation kit Thermal Cycler Reagents Protocols
Lab
ID
#1* Manual NucleoSpin1 RNA Virus Swift™ Spectrum 48 Real Time SuperScript III Platinum One-Step
qRT-PCR
Bird et al. 2007
#1a* Manual NucleoSpin1 RNA Virus Swift™ Spectrum 48 Real Time OneStep RT-PCR Kit Unpublished**
#2 Manual PureLink1 Viral RNA/
DNA
Applied Biosystems1 7500 Real-
Time
na Drosten et al, 2002
#7 Automated BioSprint 15 workstation Mx3005P qPCR AgPath-ID One-step RT-PCR kit Drosten et al, 2002
#8 Automated Arrow Viral NA iQ5 SuperScript III Platinum One-Step
qRT-PCR
Bird et al. 2007
#9 Manual QIAamp1 Viral RNA LightCycler1 480 SuperScript III Platinum One-Step
qRT-PCR
Drosten et al, 2002
#10 Manual NucleoSpin1 RNA Virus Mx3005P qPCR Sybr Green Brillant II Labeaud et al.
2011
na = not available information
* Laboratory providing multiple datasets
**Friedrich-Loefﬂer-Institut (in-house) using primer sequences published by Bird et al. (2007)
doi:10.1371/journal.pone.0142129.t003
EQA for the Diagnosis of Rift Valley Fever in the Mediterranean Basin
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RVF antibodies detection (IgG/IgM)
To detect the RVF IgG antibodies, all participating laboratories used the commercial IgG-E-
LISA assay ID Screen1 Rift Valley Fever Competition multi-species (IDvet, Grabels, France).
In addition one laboratory (#7) used the commercial INgezim FVR DR (Ingenasa, Madrid,
Spain) (#7a) and confirmed the positive ELISA results with virus neutralization. A second labo-
ratory (#9) tested two in-house IgG-ELISA assays based on: i) crude lysate of RVFV infected
cell cultures (#9a) and ii) recombinant nucleocapsid protein of RVFV (#9b).
All laboratories used the same commercial kit for the serological detection of IgM, the ID
Screen1 Rift Valley Fever IgM Capture (IDvet, Grabels, France). In addition one laboratory
(#9a) tested the samples with an in-house IgM-capture ELISA assay based on the lysate and the
supernatant of RVFV infected cell culture.
Thirteen datasets were received from the 10 laboratories participating to the RVF antibodies
detection EQA panel.
Namely 8 labs used the same unique kit to detect IgG while 2 laboratories (#7 and #9) pro-
vided the results coming from 3 different methods. Nine out of 10 laboratories reported 100%
of correct results. One laboratory, which used 2 different commercial IgG-ELISA reported
100% of correct results using one kit and all correct results except one false-positive when
using a second assay (Table 4).
Regarding the RVF IgM detection, nine out of 10 laboratories reported 100% of correct
results. One laboratory reported all correct results except one false-positive (Table 5).
In both trials aiming to detect RVF specific IgG and IgM, the laboratories failing in one
diagnostic test have a probability of giving a correct test result higher than 73.6% with a
Fig 1. Distribution of the correct results of laboratories participating to EQA for RVFV genome detection.Group 1 represents laboratories which
correctly classified 15 out of the 15 tested samples (#1a, #7, #8, #9, #10). Group 2 represents the laboratory failing to one test result (#1). Group 3 represents
the laboratory, which misidentified 5 test results (#2).
doi:10.1371/journal.pone.0142129.g001
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confidence level of 95%. The laboratories which correctly classified 15 out of 15 tested samples
have more than 82.9% probability of giving a correct test result a confidence level of 95%
(Fig 2).
Discussion
In May 2013, during the REMESA meeting held in Tunis, the IZSAM, in collaboration with
FAO and OIE, presented the first planned EQA for the diagnosis of RVF in animals. From
October to December 2013 two panels, a first one addressing the RVFV genome detection, and
a second one addressing the RVF antibodies detection, were prepared and shipped to the par-
ticipating laboratories. Results from participants were received from November 2013 to Febru-
ary 2014. In April 2014 the final report of the ring trial was sent to all participants and
organizers.
The EQA aimed to get a preliminary evaluation of the diagnostic capacities of the participat-
ing laboratories for their ability to detect RVF antibodies and RVFV genome from serum sam-
ples. The tests were intended as qualitative and, therefore, the accuracy of the results were
Table 4. Results of the EQA for RVF IgG antibodies detection.
Sample description
ID
Sample
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Species Goat Cattle Wild
rum
Wild
rum
Wild
rum
Cattle Cattle Sheep Sheep Cattle Sheep Wild
rum
Wild
rum
Sheep Cattle
IgG Pos Neg Pos Pos Pos Neg Neg Pos Pos Neg Pos Pos Pos Pos Neg ELISA
Lab n°
#1 + - + + + - - + + - + + + + - †
#2 + - + + + - - + + - + + + + - †
#3 + - + + + - - + + - + + + + - †
#4 + - + + + - - + + - + + + + - †
#5 + - + + + - - + + - + + + + - †
#6 + - + + + - - + + - + + + + - †
#7* + FP + + + - - + + - + + + + - †
#7a* + - + + + - - + + - + + + + - ‡
#8 + - + + + - - + + - + + + + - †
#9* + - + + + - - + + - + + + + - †
#9a* + - + + + - - + + - + + + + - in house
assay §
#9b* + - + + + - - + + - + + + + - in house
assay §
§
#10 + - + + + - - + + - + + + + - (†)
Wild rum: wild ruminants (Antidorcas marsupialis). Pos: RVF seropositive status; Neg: RVF seronegative status. + /—: samples identiﬁed as positive or
negative by the participants. FP: false positive result.
(†)IDvet: ID.Screen RVF competition multi- species kit.
(‡)Ingenasa: Ingezim FVR DR 13-FVR.K0.
§in house assay: test based on crude cell lysate as antigen.
§ § in house assay: test based on recombinant N protein as antigen.
* Laboratory providing multiple datasets
doi:10.1371/journal.pone.0142129.t004
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assessed on the basis of the “positive”, “negative” and/or “doubtful” results received from the
participating laboratories.
The panel for the virus genome detection consisted of 15 samples containing various con-
centrations of the Namibia 2010 strain [20]. Considering the limited genetic diversity of RVFV
strains in nature (4% differences for the nucleotide sequence and 1% for the amino acid
sequence) [7] it was considered enough to include a single, well characterized, virus strain in
the panel dedicated to the virus genome detection. The panel dedicated to RVF antibodies
detection consisted of 15 samples including domestic sheep and goats and springbok (Antidor-
cas marsupialis) sera with different levels of RVF specific IgG and/or IgM. Both panels repre-
sented a comprehensive proficiency test to assess the laboratories capacity to detect either
antibodies or viral genome in several animal species. Proficiency testing on molecular diagnosis
of RVF reported 100% concordant results in 5 of the 7 dataset submitted. One laboratory (# 1)
reported 1 false positive result with one RT-PCR assay [10], while the same sample was cor-
rectly reported as negative using a second (unpublished) protocol. One laboratory (# 2)
reported 2 false negatives and uncertain results for 3 positive samples with the assay described
by Drosten et al [11], though the same technique was used by 2 different labs (# 7, # 9) produc-
ing the expected results. Analyzing the RT-PCR performances, outside lab #2, which was below
the expected level of sensitivity, it was possible to observe some variability in Ct values ranging
from 1 to 4 Ct. The quality of purified RNA, primers, probes, PCR instruments and commer-
cial real-time RT-PCR kits used could have been responsible for the variation in sensitivity
observed in the participating labs. Furthermore the conditions applied to RT-PCR, the concen-
tration of the reaction components and time and temperature parameters, should be carefully
Table 5. Results of the EQA for RVF IgM antibodies detection.
Sample description
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Species Goat Cattle Wild
rum.
Wild
rum
Wild
rum
Cattle Cattle Sheep Sheep Cattle Sheep Wild
rum
Wild
rum
Sheep Cattle
IgM Neg Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg ELISA
Lab n°
#1 - - + + + - - - - - - + + - - †
#2 - - + + + - - - - - - + + - - †
#3 - - + + + FP - - - - - + + - - †
#4 - - + + + - - - - - - + + - - †
#5 - - + + + - - - - - - + + - - †
#6 - - + + + - - - - - - + + - - †
#7 - - + + + - - - - - - + + - - †
#8 - - + + + - - - - - - + + - - †
#9* - - + + + - - - - - - + + - - †
#9a* - - + + + - - - - - - + + - - §
#10 - - + + + - - - - - - + + - - †
Wild rum: wild ruminants (Antidorcasmarsupialis). Pos: RVF seropositive status; Neg: RVF seronegative status. + /—: samples identiﬁed as positive or
negative by the participants. FP: false positive
†IDvet: ID. Screen RVF IgM Capture
§ In-house assay: test based on crude cell lysate as antigen
* Laboratory providing multiple datasets
doi:10.1371/journal.pone.0142129.t005
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optimized to achieve efficient amplification of the specific target. All laboratories participating
to this study reported the use of real time RT-PCR technique. This confirms that the use of real
time RT-PCR has remarkably expanded, replacing conventional gel-based RT-PCR method,
although real-time requires expensive equipment and trained personnel. In similar ring trials
for RVF molecular detection [24], authors reported the use of other conventional techniques,
e.g. RT-nested PCR, RT Loop-mediated isothermal amplification (RT-LAMP) and recombi-
nase polymerase amplification (RPA) together with real-time RT-PCR for the detection of
RVFV nucleic acids.
All RT-PCR assays showed optimal performances, providing accurate determination of pos-
itive and negative results. The level of sensitivity using RT-PCR achieved by the participants to
this EQA is not different from that reported in the study of Escadafal et al. [24].
A total of 4 commercially available ELISA and 3 in-house assays were used by the participat-
ing laboratories for antibodies detection. All participants used IDvet ELISA kits (ID Screen1
Rift Valley Fever Competition Multi-species for IgG detection and ID Screen1 Rift Valley
Fever IgM Capture for IgM detection). One laboratory (#7) used in parallel the commercial
INgezim FVR DR (Ingenasa, Madrid, Spain) for IgG detection. One laboratory (#9) tested 2 in-
house ELISA assays for IgG detection, based on recombinant nucleocapsid protein of RVFV
and crude lysate of RVFV infected cell cultures respectively. The same laboratory evaluated in-
house ELISA assay for IgM using infected cell lysate as antigen. Furthermore one laboratory
(#7) confirmed the ELISA positive samples with virus neutralization. Overall, the in-house and
commercial assays used in the EQA performed with no variation. The EQA presented here
provided a good overview on the laboratory capacities for the diagnosis of RVF in animals in
Fig 2. Distribution of the correct results of laboratories participating to the EQAs for RVF antibodies detection (IgG and IgM).Group 1 includes
laboratories, which correctly classified 15 out of the 15 tested samples, Group 2 represents the laboratory failing to one test result. For IgG EQA group 1
includes the laboratories: #1, #2, #3, #4, #5, #6, #7a, #8, #9, #9a, #9b, #10, while in group 2 #7. For IgM EQA group 1 includes #1, #2, #4, #5, #6, #7, #7a, #8,
#9, #9a, #9b, #10 and group 2 #3.
doi:10.1371/journal.pone.0142129.g002
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the Western Mediterranean Region, showing that the participating laboratories were able to
perform the tests and provide the results in time. The use of a limited set of diagnostic assays
indicated that harmonized procedures are already being applied by the participating laborato-
ries, allowing the comparison of results and thus indicating that an efficient regional surveil-
lance system, which is one of the objectives of REMESA, may be put in place. Furthermore the
combination in the same EQA of molecular and serological techniques, which allows a comple-
mentary diagnostic approach to RVF, is particularly important for diagnosis and monitoring
mainly in countries where RVFV is not endemic.
Otherwise, the use of the same tests by all participants may limit the possibility to recognize
the emergence of unusual virus strains evoking different immune responses [25].Therefore the
use of a wider set of diagnostic methods should be encouraged.
To guarantee a constant high quality level of RVF diagnosis in the region and to ensure the
reliability of the diagnostic results we recommend conducting EQA studies on a regular basis.
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